Constitutive expression of murine decay-accelerating factor 1 is controlled by the transcription factor Sp1

Journal of Immunology

Volumn 177, Issue 6, 2006, Pages 3837-3847

  Cauvi, David M ^a   Cauvi, Gabrielle ^a   Pollard, K Michael ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE; DECAY ACCELERATING FACTOR; DECAY ACCELERATING FACTOR 1; GUANINE; REGULATOR PROTEIN; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL LINE; CELL STRAIN 3T3; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT INHIBITION; DAF1 GENE; DNA FLANKING REGION; DNA STRUCTURE; EMBRYO; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; GENE EXPRESSION REGULATION; IMMUNE RESPONSE; INNATE IMMUNITY; MOLECULAR CLONING; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSCRIPTION REGULATION; TRANSCRIPTIONAL REGULATORY ELEMENT;

EID: 33748501922     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.6.3837     Document Type: Article

References (60)

1. Lublin, D. M., and J. P. Atkinson. 1989. Decay-accelerating factor: biochemistry, molecular biology, and function. Annu. Rev. Immunol. 7: 35-58.
2. Song, W. C. 2004. Membrane complement regulatory proteins in autoimmune and inflammatory tissue injury. Curr. Dir. Autoimmun. 7: 181-199.
3. Liu, J., T. Miwa, B. Hilliard, Y. Chen, J. D. Lambris, A. D. Wells, and W. C. Song. 2005. The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J. Exp. Med. 201: 567-577.
4. Heeger, P. S., P. N. Lalli, F. Lin, A. Valujskikh, J. Liu, N. Muqim, Y. Xu, and M. E. Medof. 2005. Decay-accelerating factor modulates induction of T cell immunity. J. Exp. Med. 201: 1523-1530.
5. Lea, S. 2002. Interactions of CD55 with non-complement ligands. Biochem. Soc. Trans. 30: 1014-1019.
6. Hamann, J., B. Vogel, G. M. van Schijndel, and R. A. van Lier. 1996. The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF). J. Exp. Med. 184: 1185-1189.
7. Visser, L., A. F. de Vos, J. Hamann, M. J. Melief, M. van Meurs, R. A. van Lier, J. D. Laman, and R. Q. Hintzen. 2002. Expression of the EGF-TM7 receptor CD97 and its ligand CD55 (DAF) in multiple sclerosis. J. Neuroimmunol. 132: 156-163.
8. Leemans, J. C., A. A. te Velde, S. Florquin, R. J. Bennink, K. de Bruin, R. A. van Lier, T. van der Poll, and J. Hamann. 2004. The epidermal growth factor-seven transmembrane (EGF-TM7) receptor CD97 is required for neutrophil migration and host defense. J. Immunol. 172: 1125-1131.
9. Davis, L. S., S. S. Patel, J. P. Atkinson, and P. E. Lipsky. 1988. Decay-accelerating factor functions as a signal transducing molecule for human T cells. J. Immunol. 141: 2246-2252.
10. Shibuya, K., T. Abe, and T. Fujita. 1992. Decay-accelerating factor functions as a signal transducing molecule for human monocytes. J. Immunol. 149: 1758-1762.
11. fyn 1. J. Immunol. 149: 3535-3541.
12. Post, T. W., M. A. Arce, M. K. Liszewski, E. S. Thompson, J. P. Atkinson, and D. M. Lublin. 1990. Structure of the gene for human complement protein decay accelerating factor. J. Immunol. 144: 740-744.
13. Nicholson-Weller, A., J. P. March, C. E. Rosen, D. B. Spicer, and K. F. Austen. 1985. Surface membrane expression by human blood leukocytes and platelets of decay-accelerating factor, a regulatory protein of the complement system. Blood 65: 1237-1244.
14. Medof, M. E., E. I. Walter, J. L. Rutgers, D. M. Knowles, and V. Nussenzweig. 1987. Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J. Exp. Med. 165: 848-864.
15. Spicer, A. P., M. F. Seldin, and S. J. Gendler. 1995. Molecular cloning and chromosomal localization of the mouse decay-accelerating factor genes: duplicated genes encode glycosylphosphatidylinositol-anchored and transmembrane forms. J. Immunol. 155: 3079-3091.
16. Lin, F., Y. Fukuoka, A. Spicer, R. Ohta, N. Okada, C. L. Harris, S. N. Emancipator, and M. E. Medof. 2001. Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes: exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies. Immunology 104: 215-225.
17. Miwa, T., X. Sun, R. Ohta, N. Okada, C. L. Harris, B. P. Morgan, and W. C. Song. 2001. Characterization of glycosylphosphatidylinositol-anchored decay accelerating factor (GPI-DAF) and transmembrane DAF gene expression in wild-type and GPI-DAF gene knockout mice using polyclonal and monoclonal antibodies with dual or single specificity. Immunology 104: 207-214.
18. Thomas, D. J., and D. M. Lublin. 1993. Identification of 5′-flanking regions affecting the expression of the human decay accelerating factor gene and their role in tissue-specific expression. J. Immunol. 150: 151-160.
19. Song, W. C., C. Deng, K. Raszmann, R. Moore, R. Newbold, J. A. McLachlan, and M. Negishi. 1996. Mouse decay-accelerating factor: selective and tissue-specific induction by estrogen of the gene encoding the glycosylphosphatidylinositol-anchored form. J. Immunol. 157: 4166-4172.
20. Spiller, O. B., O. Criado-Garcia, S. Rodriguez De Cordoba, and B. P. Morgan. 2000. Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack. Clin. Exp. Immunol. 121: 234-241.
21. Cocuzzi, E. T., D. S. Bardenstein, A. Stavitsky, N. Sundarraj, and M. E. Medof. 2001. Upregulation of DAF (CD55) on orbital fibroblasts by cytokines: differential effects of TNF-β and TNF-α. Curr. Eye Res. 23: 86-92.
22. Ahmad, S. R., E. A. Lidington, R. Ohta, N. Okada, M. G. Robson, K. A. Davies, M. Leitges, C. L. Harris, D. O. Haskard, and J. C. Mason. 2003. Decay-accelerating factor induction by tumour necrosis factor-α, through a phosphatidylinositol-3 kinase and protein kinase C-dependent pathway, protects murine vascular endothelial cells against complement deposition. Immunology 110: 258-268.
23. 2 regulates the complement inhibitor CD55/decay-accelerating factor in colorectal cancer. J. Biol. Chem. 280: 476-483.
24. Andoh, A., K. Kinoshita, I. Rosenberg, and D. K. Podolsky. 2001. Intestinal trefoil factor induces decay-accelerating factor expression and enhances the protective activities against complement activation in intestinal epithelial cells. J. Immunol. 167: 3887-3893.
25. Saklatvala, J., J. Dean, and A. Clark. 2003. Control of the expression of inflammatory response genes. Biochem. Soc. Symp. 70: 95-106.
26. Kendall, G., H. Crankson, E. Ensor, D. M. Lublin, and D. S. Latchman. 1996. Activation of the gene encoding decay accelerating factor following nerve growth factor treatment of sensory neurons is mediated by promoter sequences within 206 bases of the transcriptional start site. J. Neurosci. Res. 45: 96-103.
27. Louis, N. A., K. E., Hamilton, T. Kong, and S. P. Colgan. 2005. HIF-dependent induction of apical CD55 coordinates epithelial clearance of neutrophils. FASEB J. 19: 950-959.
28. Ewulonu, U. K., L. Ravi, and M. E. Medof. 1991. Characterization of the decay-accelerating factor gene promoter region. Proc. Natl. Acad. Sci. USA 88: 4675-4679.
29. Birney, E., D. Andrews, M. Caccamo, Y. Chen, L. Clarke, G. Coates, T. Cox, F. Cunningham, V. Curwen, T. Cutts, et al. 2006. Ensembl 2006. Nucleic Acids Res. 34: D556-D561.
30. Hibma, M. H., S. J. Ely, and L. Crawford. 1994. A non-radioactive assay for the detection and quantitation of a DNA binding protein. Nucleic Acids Res. 22: 3806-3807.
31. Blake, M. C., R. C. Jambou, A. G. Swick, J. W. Kahn, and J. C. Azizkhan. 1990. Transcriptional initiation is controlled by upstream GC-box interactions in a TATAA-less promoter. Mol. Cell. Biol. 10: 6632-6641.
32. Suske, G. 1999. The Sp-family of transcription factors. Gene 238: 291-300.
33. Philipsen, S., and G. Suske. 1999. A tale of three fingers: the family of mammalian Sp/XKLF transcription factors. Nucleic Acids Res. 27: 2991-3000.
34. Suske, G. 2000. Transient transfection of Schneider cells in the study of transcription factors. Methods Mol. Biol 130: 175-187.
35. Johannessen, M., M. P. Delghandi, and U. Moens. 2004. What turns CREB on? Cell. Signal. 16: 1211-1227.
36. Moutabarrik, A., I. Nakanishi, M. Namiki, T. Kara, M. Matsumoto, M. Ishibashi, A. Okuyama, D. Zaid, and T. Seya. 1993. Cytokine-mediated regulation of the surface expression of complement regulatory proteins, CD46(MCP), CD55(DAF), and CD59 on human vascular endothelial cells. Lymphokine Cytokine Res. 12: 167-172.
37. Iborra, A., M. Mayorga, N. Llobet, and P. Martinez. 2003. Expression of complement regulatory proteins [membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59)] in endometrial stressed cells. Cell. Immunol. 223: 46-51.
38. Li, W., T. Tada, T. Miwa, N. Okada, J. Ito, H. Okada, H. Tateyama, and T. Eimoto. 1999. mRNA expression of complement components and regulators in rat arterial smooth muscle cells. Microbiol. Immunol. 43: 585-593.
39. Kruys, V., P. Thompson, and B. Beutler. 1993. Extinction of the tumor necrosis factor locus, and of genes encoding the lipopolysaccharide signaling pathway. J. Exp. Med. 177: 1383-1390.
40. Cui, W., D. Hourcade, T. Post, A. C. Greenlund, J. P. Atkinson, and V. Kumar. 1993. Characterization of the promoter region of the membrane cofactor protein (CD46) gene of the human complement system and comparison to a membrane cofactor protein-like genetic element. J. Immunol. 151: 4137-4146.
41. Holguin, M. H., G. B. Martin, T. Eggett, and C. J. Parker. 1996. Analysis of the gene that encodes the complement regulatory protein, membrane inhibitor of reactive lysis (CD59): identification of an alternatively spliced exon and characterization of the transcriptional regulatory regions of the promoter. J. Immunol. 157: 1659-1668.
42. Kim, J. H., S. Lee, and S. Y. Choe. 1999. Characterization of the human CR1 gene promoter. Biochem. Mol. Biol. Int. 47: 655-663.
43. Zahedi, K., A. E. Prada, and A. E. Davis, 3rd. 1994. Transcriptional regulation of the C1 inhibitor gene by γ-interferon. J. Biol. Chem. 269: 9669-9674.
44. Arenzana, N., and S. Rodriguez de Cordoba. 1996. Promoter region of the human gene coding for β-chain of C4b binding protein: hepatocyte nuclear factor-3 and nuclear factor-I/CTF transcription factors are required for efficient expression of C4BPB in HepG2 cells. J. Immunol. 156: 168-175.
45. Williams, S. A., and D. P. Vik. 1997. Characterization of the 5′ flanking region of the human complement factor H gene. Scand. J. Immunol. 45: 7-15.
46. Minta, J. O., M. Fung, S. Turner, R. Eren, L. Zemach, M. Rits, and G. Goldberger. 1998. Cloning and characterization of the promoter for the human complement factor I (C3b/C4b inactivator) gene. Gene 208: 17-24.
47. Smale, S. T., and J. T. Kadonaga. 2003. The RNA polymerase II core promoter. Annu. Rev. Biochem. 72: 449-479.
48. Pugh, B. F., and R. Tjian. 1991. Transcription from a TATA-less promoter requires a multisubunit TFIID complex. Genes Dev. 5: 1935-1945.
49. Emami, K. H., T. W. Burke, and S. T. Smale. 1998. Sp1 activation of a TATA-less promoter requires a species-specific interaction involving transcription factor IID. Nucleic Acids Res. 26: 839-846.
50. Ryu, S., S. Zhou, A. G. Ladurner, and R. Tjian. 1999. The transcriptional cofactor complex CRSP is required for activity of the enhancer-binding protein Sp1. Nature 397: 446-450.
51. Carcedo, M. T., J. M. Iglesias, P. Bances, R. O. Morgan, and M. P. Fernandez. 2001. Functional analysis of the human annexin A5 gene promoter: a downstream DNA element and an upstream long terminal repeat regulate transcription. Biochem. J. 356: 571-579.
52. Koga, T., M. A. Suico, H. Nakamura, M. Taura, Z. Lu, T. Shuto, T. Okiyoneda, and H. Kai. 2005. Sp1-dependent regulation of myeloid Elf-1 like factor in human epithelial cells. FEBS Lett. 579: 2811-2816.
53. Boisclair, Y. R., A. L. Brown, S. Casola, and M. M. Rechler. 1993. Three clustered Sp1 sites are required for efficient transcription of the TATA-less promoter of the gene for insulin-like growth factor-binding protein-2 from the rat. J. Biol. Chem. 268: 24892-24901.
54. Courey, A. J., D. A. Holtzman, S. P. Jackson, and R. Tjian. 1989. Synergistic activation by the glutamine-rich domains of human transcription factor Sp1. Cell 59: 827-836.
55. Chen, X., J. C. Azizkhan, and D. C. Lee. 1992. The binding of transcription factor Sp1 to multiple sites is required for maximal expression from the rat transforming growth factor α promoter. Oncogene 7: 1805-1815.
56. Dusing, M. R., and D. A. Wiginton. 1994. Sp1 is essential for both enhancer-mediated and basal activation of the TATA-less human adenosine deaminase promoter. Nucleic Acids Res. 22: 669-677.
57. Tone, M., Y. Tone, J. M. Babik, C. Y. Lin, and H. Waldmann. 2002. The role of Sp1 and NF-κB in regulating CD40 gene xpression. J. Biol. Chem. 277: 8890-8897.
58. Nagata, D., E. Suzuki, H. Nishimatsu, H. Satonaka, A. Goto, M. Omata, and Y. Hirata. 2001. Transcriptional activation of the cyclin D1 gene is mediated by multiple cis-elements, including SP1 sites and a cAMP-responsive element in vascular endothelial cells. J. Biol. Chem. 276: 662-669.
59. Lui, W. Y., K. L. Sze, and W. M. Lee. 2006. Nectin-2 expression in testicular cells is controlled via the functional cooperation between transcription factors of the Sp1, CREB, and AP-1 families. J. Cell. Physiol. 207: 144-157.
60. Felinski, E. A., J. Kim, J. Lu, and P. G. Quinn. 2001. Recruitment of an RNA polymerase II complex is mediated by the constitutive activation domain in CREB, independently of CREB phosphorylation. Mol. Cell. Biol. 21: 1001-1010.